Showing results (81-90 of 88) with videos related to
Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 88 results.
Bioorganic & Medicinal Chemistry Letters|November 1, 2003
Design and synthesis of novel RXR-selective modulators with improved pharmacological profilePierre-Yves Michellys, Marcus F Boehm, Jyun-Hung Chen, et al.Journal of Medicinal Chemistry|September 5, 2003
Design, synthesis, and structure-activity relationship studies of novel 6,7-locked-[7-(2-alkoxy-3,5-dialkylbenzene)-3-methylocta]-2,4,6-trienoic acidsPierre-Yves Michellys, Robert J Ardecky, Jyun-Hung Chen, et al.The Journal of Biological Chemistry|February 26, 1999
Novel peroxisome proliferator-activated receptor (PPAR) gamma and PPARdelta ligands produce distinct biological effectsJ Berger, M D Leibowitz, T W Doebber, et al.Nature Biotechnology|October 2, 2019
Integrated genomic profiling expands clinical options for patients with cancerNike Beaubier, Martin Bontrager, Robert Huether, et al.Clinical Breast Cancer|January 15, 2021
Real-world Evidence of Diagnostic Testing and Treatment Patterns in US Patients With Breast Cancer With Implications for Treatment Biomarkers From RNA Sequencing DataLouis E Fernandes, Caroline G Epstein, Alexandria M Bobe, et al.Journal of Medicinal Chemistry|June 13, 2003
Novel (2E,4E,6Z)-7-(2-alkoxy-3,5-dialkylbenzene)-3-methylocta-2,4,6-trienoic acid retinoid X receptor modulators are active in models of type 2 diabetesP Y Michellys, R J Ardecky, J H Chen, et al.Endocrinology|November 5, 2005
Biological characterization of a heterodimer-selective retinoid X receptor modulator: potential benefits for the treatment of type 2 diabetesMark D Leibowitz, Robert J Ardecky, Marcus F Boehm, et al.Cell Reports|July 28, 2021
A pan-cancer organoid platform for precision medicineBrian M Larsen, Madhavi Kannan, Lee F Langer, et al.Pageof 9